Small · 16 Nov 2026
Multimodal Nanohybrid Artificial Antibodies as PD‐L1 Immune Checkpoint Antagonists for Potentiated Combination Cancer Immunotherapy
Sin Lee, Yujin Choi, Yoonhee So, Yejoo Yu, Chanhee Choi, Hongwon Kim, Sohyun Moon, Seongyeon Choi, Hwankyu Lee, Jong‐Ho Kimh-index 19
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
ABSTRACT Monoclonal antibody–based PD‐1/PD‐L1 blockade immunotherapy is an innovative approach to cancer treatment. However, its clinical efficacy remains limited, with low response rates in patients, requiring multimodal therapeutic approaches. This study reports the development of synthetic nanohybrid artificial antibodies (SNA) with both PD‐L1 blockade and photothermal effects as multimodal immune checkpoint antagonists for effective combination cancer immunotherapy. Multimodal SNAs are prepared by assembling multivalent tripeptide recognition phases onto rigid scaffolds of WS 2 or MoSe 2 nanosheets with photothermal effect. The SNAs, comprising an FNP tripeptide assembly on nanosheets (MoSe 2 ‐FNP & WS 2 ‐FNP), selectively bind to PD‐L1 with sub‐nanomolar apparent affinity (0.785 nM), thereby effectively blocking its interaction with PD‐1 on T cells. Thorough experimental and computational results reveal that the recognition selectivity of the SNAs for PD‐L1 is attributed to their multivalent hydrogen bonds and hydrophobic interactions with the PD‐L1 epitope. The multimodal MoSe 2 ‐FNP more effectively eradicates tumor cells by combining a PD‐L1 blockade with photothermal effect. The multimodal MoSe 2 ‐FNP‐based combination immunotherapy accelerates the infiltration of antitumoral immune cells into solid tumors in mice, and its therapeutic efficacy is significantly enhanced compared with monoclonal antibody treatment. This SNA‐based cancer immunotherapy thus holds considerable promise as an effective therapeutic avenue for cancer treatment.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Jong‐Ho Kim has the highest h-index among the authors (19).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (38)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 18 more references
A free account opens the rest of the citing papers and references on every paper’s page.